Stanford University researchers reported retrospective cohort findings suggesting semaglutide is associated with a reduced risk of bone fractures. The analysis used electronic health record data covering more than 161 million patients from U.S. hospitals and academic centers. The results build on semaglutide’s weight-loss and metabolic effects by extending inquiry into musculoskeletal outcomes, a domain with high relevance to long-term safety and durability as GLP-1 use broadens. Because the study is retrospective, it frames a signal rather than a prospective causality test, but it nonetheless provides additional endpoints for real-world effectiveness and risk-benefit evaluations of GLP-1 therapies.